551 related articles for article (PubMed ID: 25578949)
61. Electroencephalographic (EEG) Biomarkers in Genetic Neurodevelopmental Disorders.
Goodspeed K; Armstrong D; Dolce A; Evans P; Said R; Tsai P; Sirsi D
J Child Neurol; 2023 May; 38(6-7):466-477. PubMed ID: 37264615
[TBL] [Abstract][Full Text] [Related]
62. [Activity-dependent regulation of dendritic spine morphology and brain diseases].
Yamagata K; Sugiura H; Yasuda S
Nihon Yakurigaku Zasshi; 2013 Sep; 142(3):106-11. PubMed ID: 24025490
[No Abstract] [Full Text] [Related]
63. New innovations: therapeutic opportunities for intellectual disabilities.
Picker JD; Walsh CA
Ann Neurol; 2013 Sep; 74(3):382-90. PubMed ID: 24038210
[TBL] [Abstract][Full Text] [Related]
64. Emerging pharmacotherapies for neurodevelopmental disorders.
Wetmore DZ; Garner CC
J Dev Behav Pediatr; 2010 Sep; 31(7):564-81. PubMed ID: 20814256
[TBL] [Abstract][Full Text] [Related]
65. A Fragile Balance: Dendritic Spines, Learning, and Memory.
McCann RF; Ross DA
Biol Psychiatry; 2017 Jul; 82(2):e11-e13. PubMed ID: 28645359
[No Abstract] [Full Text] [Related]
66. Dendritic spine and synapse pathology in chromatin modifier-associated autism spectrum disorders and intellectual disability.
Ford TJL; Jeon BT; Lee H; Kim WY
Front Mol Neurosci; 2022; 15():1048713. PubMed ID: 36743289
[TBL] [Abstract][Full Text] [Related]
67. Stem cells and modeling of autism spectrum disorders.
Freitas BC; Trujillo CA; Carromeu C; Yusupova M; Herai RH; Muotri AR
Exp Neurol; 2014 Oct; 260():33-43. PubMed ID: 23036599
[TBL] [Abstract][Full Text] [Related]
68. [Therapeutic approaches in autism spectrum disorders].
Ruggieri VL; Arberas CL
Rev Neurol; 2015 Feb; 60 Suppl 1():S45-9. PubMed ID: 25726823
[TBL] [Abstract][Full Text] [Related]
69. Common Defects of Spine Dynamics and Circuit Function in Neurodevelopmental Disorders: A Systematic Review of Findings From
Nakai N; Takumi T; Nakai J; Sato M
Front Neurosci; 2018; 12():412. PubMed ID: 29970983
[No Abstract] [Full Text] [Related]
70. Rethinking Intellectual Disability from Neuro- to Astro-Pathology.
Fernández-Blanco Á; Dierssen M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261169
[TBL] [Abstract][Full Text] [Related]
71. mTOR-Dependent Spine Dynamics in Autism.
Chaudry S; Vasudevan N
Front Mol Neurosci; 2022; 15():877609. PubMed ID: 35782388
[TBL] [Abstract][Full Text] [Related]
72. Dendritic spines and their role in the pathogenesis of neurodevelopmental and neurological disorders.
Akhgari A; Michel TM; Vafaee MS
Rev Neurosci; 2024 Mar; ():. PubMed ID: 38440811
[TBL] [Abstract][Full Text] [Related]
73. Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders.
Wang H
Front Behav Neurosci; 2014; 8():104. PubMed ID: 24723866
[No Abstract] [Full Text] [Related]
74. Autism spectrum disorders: emerging mechanisms and mechanism-based treatment.
Wang H; Doering LC
Front Cell Neurosci; 2015; 9():183. PubMed ID: 26029053
[No Abstract] [Full Text] [Related]
75. Fetal and sociocultural environments and autism.
Lord C
Am J Psychiatry; 2013 Apr; 170(4):355-8. PubMed ID: 23545788
[No Abstract] [Full Text] [Related]
76. Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid.
Nicolini C; Ahn Y; Michalski B; Rho JM; Fahnestock M
Acta Neuropathol Commun; 2015 Jan; 3():3. PubMed ID: 25627160
[TBL] [Abstract][Full Text] [Related]
77. Autism and the synapse: emerging mechanisms and mechanism-based therapies.
Ebrahimi-Fakhari D; Sahin M
Curr Opin Neurol; 2015 Apr; 28(2):91-102. PubMed ID: 25695134
[TBL] [Abstract][Full Text] [Related]
78. Hyperactivity of newborn Pten knock-out neurons results from increased excitatory synaptic drive.
Williams MR; DeSpenza T; Li M; Gulledge AT; Luikart BW
J Neurosci; 2015 Jan; 35(3):943-59. PubMed ID: 25609613
[TBL] [Abstract][Full Text] [Related]
79. Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.
Wang H; Pati S; Pozzo-Miller L; Doering LC
Front Cell Neurosci; 2015; 9():55. PubMed ID: 25767435
[TBL] [Abstract][Full Text] [Related]
80. Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression.
Chung W; Choi SY; Lee E; Park H; Kang J; Park H; Choi Y; Lee D; Park SG; Kim R; Cho YS; Choi J; Kim MH; Lee JW; Lee S; Rhim I; Jung MW; Kim D; Bae YC; Kim E
Nat Neurosci; 2015 Mar; 18(3):435-43. PubMed ID: 25622145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
